AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Theratechnologies Inc. (TSX:TH)
1.69 CAD
-0.040 2.312%Sponsored Reports
Loading...
| Previous Close (in CAD) | 1.73 |
|---|---|
| Change | -0.040 2.312% |
| 52 W H/L (in CAD) | 3.430/1.590 |
| EBITDA (in CAD) | 14.398M |
| PE Ratio | -- |
| Volume | 13988 |
| Diluted Eps TTM | -0.06 |
| Total Assets (in CAD) | 77.769M |
|---|---|
| Total Liabilities (in CAD) | 98.639M |
| Revenue TTM (in CAD) | 84.316M |
| Cash (in CAD) | 34.097M |
| Market Cap (in CAD) | 81.844 M |
| Revenue Per Share TTM | 1.865 |
| Gross Profit TTM (in CAD) | 56.219M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Employees: 103
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Paul Lévesque | Pres, CEO & Director | 1964 |
| 2. | Mr. Philippe Dubuc M.B.A., MBA | Sr. VP & CFO | 1967 |
| 3. | Dr. Christian Marsolais Ph.D. | Sr. VP & Chief Medical Officer | 1963 |
| 4. | Mr. John Leasure | Global Commercial Officer | 1965 |
| 5. | Ms. Elif McDonald | Sr. Director of Investor Relations | NA |
| 6. | Mr. Jocelyn Lafond L.L.M., LL.B. | Gen. Counsel & Corp. Sec. | 1968 |
| 7. | Mr. Denis Boucher B.A., L.L.B. | VP of Communications & Corp. Affairs | 1966 |
| 8. | Hon. Andre Dupras M.Sc. | VP of HR | 1964 |
| 9. | Mr. Paul Lévesque | President, CEO & Director | 1964 |
| 10. | Mr. Philippe Dubuc M.B.A., MBA | Senior VP & CFO | 1967 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
FRX
Fennec Pharmaceuticals Inc |
+0.190 3.146% | 6.18 | 58.900 | 212.766 | 3.266 | 57.980 | 2.140 | 15.889 |
|
MDNA
Medicenna Therapeutics Corp |
+0.050 2.959% | 1.7 | 0.000 | 204.082 | 0.000 | 6.915 | 0.000 | -6.109 |
|
EPRX
Eupraxia Pharmaceuticals Inc |
+0.300 7.692% | 4.05 | 0.000 | 0.000 | 0.000 | 7.620 | 0.000 | -3.882 |
|
ONC
Oncolytics Biotech Inc |
-0.050 3.401% | 1.46 | 0.000 | 0.000 | 0.000 | 6.212 | 0.000 | -2.446 |
Income Statement
(Currency in CAD)| Breakdown | 30-11-2022 | 30-11-2021 | 30-11-2020 | 30-11-2019 | 30-11-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -46.794M | -31.662M | -22.651M | -12.496M | -5.78M |
| Minority Interest | - | - | - | - | - |
| Net Income | -47.237M | -31.725M | -22.667M | -12.547M | -4.529M |
| Selling General Administrative | 17.356M | 14.616M | 12.23M | 8.33M | 5.686M |
| Gross Profit | 53.778M | 46.563M | 39.151M | 37.14M | 31.126M |
| Reconciled Depreciation | 12.471M | 8.748M | 8.52M | 7.495M | 4.148M |
| Ebit | -39.908M | -25.236M | -17.957M | -7.455M | -3.301M |
| Ebitda | -27.156M | -16.324M | -9.178M | 0.04M | 0.847M |
| Depreciation And Amortization | 12.752M | 8.912M | 8.779M | 7.495M | 4.148M |
| Operating Income | -39.908M | -25.236M | -17.957M | -7.455M | -3.416M |
| Other Operating Expenses | 119.965M | 95.059M | 84.01M | 71.729M | 47.515M |
| Interest Expense | 6.497M | 5.664M | 5.362M | 4.99M | 2.479M |
| Tax Provision | 0.443M | 0.063M | 0.016M | 0M | -1.269M |
| Interest Income | 7.208M | 0.195M | 4.654M | 3.944M | 2.371M |
| Net Interest Income | -6.216M | -6.426M | -5.103M | -3.932M | -2.203M |
| Income Tax Expense | 0.443M | 0.063M | 0.016M | 0.051M | -1.252M |
| Total Revenue | 80.057M | 69.823M | 66.053M | 63.216M | 44.099M |
| Total Operating Expenses | 93.686M | 71.799M | 57.108M | 45.653M | 34.542M |
| Cost Of Revenue | 26.279M | 23.26M | 26.902M | 26.076M | 12.973M |
| Total Other Income Expense Net | -6.886M | -6.426M | -4.694M | -5.041M | -2.365M |
| Net Income From Continuing Ops | -47.237M | -31.725M | -22.667M | -12.496M | -4.529M |
| Net Income Applicable To Common Shares | -47.237M | -31.725M | -22.667M | -12.496M | -4.7M |
Balance Sheet
(Currency in CAD)| Breakdown | 30-11-2023 | 30-11-2022 | 30-11-2021 | 30-11-2020 | 30-11-2019 |
|---|---|---|---|---|---|
| Total Assets | 77.769M | 93.26M | 119.212M | 100.142M | 117.555M |
| Intangible Assets | 12.496M | 15.009M | 23.829M | 31.852M | 39.684M |
| Other Current Assets | 3.293M | 8.268M | 11.485M | 5.709M | 4.511M |
| Total Liab | 98.639M | 115.831M | 101.452M | 96.918M | 92.721M |
| Total Stockholder Equity | -20.87M | -22.571M | 17.76M | 3.224M | 24.834M |
| Other Current Liab | 32.559M | 36.09M | 58.066M | 23.934M | 23.968M |
| Common Stock | 363.927M | 338.751M | 335.752M | 287.312M | 287.035M |
| Capital Stock | 363.927M | 338.751M | 335.752M | 287.312M | 287.035M |
| Retained Earnings | -408.659M | -382.649M | -335.248M | -300.129M | -277.462M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 1.792M | 0.621M | - | - |
| Cash | 34.097M | 23.856M | 20.399M | 12.737M | 28.661M |
| Cash And Equivalents | - | 9.214M | 19.955M | 8.031M | 11.964M |
| Total Current Liabilities | 47.294M | 114.279M | 45.076M | 41.919M | 37.144M |
| Current Deferred Revenue | 0.038M | 0.038M | 0.054M | 0.05M | 0.07M |
| Net Debt | 24.871M | 42.855M | 36.346M | 42.646M | 22.08M |
| Short Term Debt | 7.707M | 65.265M | 0.463M | 0.425M | 20.551M |
| Short Long Term Debt | 7.286M | 64.789M | - | - | - |
| Short Long Term Debt Total | 58.968M | 66.711M | 56.745M | 55.383M | 50.741M |
| Other Stockholder Equity | 23.178M | 20.942M | 17.3M | 16.522M | 15.24M |
| Property Plant Equipment | - | 3.089M | 2.854M | 3.483M | 1.071M |
| Total Current Assets | 63.297M | 73.37M | 91.908M | 64.807M | 76.181M |
| Long Term Investments | - | - | - | 0M | 0.619M |
| Short Term Investments | 6.29M | 9.214M | 19.955M | 8.031M | 11.964M |
| Net Receivables | 13.551M | 12.344M | 10.928M | 13.185M | 10.116M |
| Long Term Debt | 50.688M | 0M | 54.227M | 52.403M | 55.311M |
| Inventory | 6.066M | 19.688M | 29.141M | 25.145M | 20.929M |
| Accounts Payable | 6.99M | 12.886M | 15.526M | 17.51M | 13.106M |
| Accumulated Other Comprehensive Income | 0.684M | 0.385M | -0.044M | -0.481M | 0.021M |
| Non Currrent Assets Other | - | 1.792M | 0.621M | - | 12.204M |
| Non Current Assets Total | 14.472M | 19.89M | 27.304M | 35.335M | 41.374M |
| Capital Lease Obligations | 0.994M | 1.922M | 2.518M | 2.98M | - |
| Long Term Debt Total | - | 1.446M | 56.282M | 54.958M | 55.311M |
Cash Flow
(Currency in CAD)| Breakdown | 30-11-2022 | 30-11-2021 | 30-11-2020 | 30-11-2019 | 30-11-2018 |
|---|---|---|---|---|---|
| Investments | 8.682M | -12.116M | 4.776M | -0.13M | -10.691M |
| Total Cashflows From Investing Activities | 8.682M | -12.454M | 4.776M | -0.13M | -9.918M |
| Total Cash From Financing Activities | 9.656M | 34.557M | -7.229M | -6.807M | 46.889M |
| Net Income | -47.237M | -31.725M | -22.667M | -12.496M | -4.529M |
| Change In Cash | 3.457M | 7.662M | -15.924M | -10.336M | 37.719M |
| Begin Period Cash Flow | 20.399M | 12.737M | 28.661M | 38.997M | 1.326M |
| End Period Cash Flow | 23.856M | 20.399M | 12.737M | 28.661M | 39.045M |
| Total Cash From Operating Activities | -14.692M | -14.477M | -13.554M | -3.391M | -0.334M |
| Depreciation | 12.471M | 8.748M | 8.52M | 7.495M | 4.148M |
| Other Cashflows From Investing Activities | 9.667M | -0.172M | 0.361M | 1.202M | 0.754M |
| Dividends Paid | - | 0M | 0M | 0M | - |
| Change To Inventory | 8.991M | -4.187M | -4.872M | -9.861M | -3.901M |
| Sale Purchase Of Stock | 2.981M | 47.339M | 0.145M | 0.11M | 0.633M |
| Other Cashflows From Financing Activities | 36.047M | -10.81M | -6.661M | -6.807M | 57.069M |
| Capital Expenditures | 0.985M | 0.166M | 0.032M | 3.622M | 0.039M |
| Change In Working Capital | 13.017M | 0.242M | -6.274M | -3.662M | -0.037M |
| Other Non Cash Items | 2.742M | 6.326M | 5.44M | 4.185M | 0.509M |
| Free Cash Flow | -15.677M | -14.643M | -13.586M | -7.013M | -0.374M |
No data found
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
